申请人:BRISTOL-MYERS SQUIBB COMPANY
公开号:EP0618221A3
公开(公告)日:1995-02-15
Inhibition of farnesyl protein transferase is effected by compounds of the formula
its enantiomers, diastereomers, pharmaceutically acceptable salts, prodrugs or solvates thereof, wherein:
A₁ and A₂ are each independently H, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, phenyl or substituted phenyl;
G₁ is S or O;
G₂ is H, -C(O)OH, -C(O)NH₂, 5-tetrazolyl, -C(O)N(R₇)OH or -CH₂OH;
X is O or R₈N;
Y and Z are each independently -CH₂- or -C(O)-;
R₁, R₂, R₃, R₄, R₅, R₆ and R₇ are each independently H or alkyl;
R₁ may also be alkanoyl,
R₁ and A₁ taken together may be -(CH₂)m;
R₈ is H, alkyl, phenyl, phenylalkyl, substituted phenyl, (substituted phenyl)alkyl or -C(O)R₉; R₉ is H, alkyl, phenyl, phenylalkyl, substituted phenyl or (substituted phenyl)alkyl;
m is 3 or 4;
n is 0, 1 or 2;
p is 0, 1 or 2; and
q is 0 or 1, with the proviso that when p is 0, then q is also 0.
该公式的化合物通过其对映体、非对映体、药用可接受的盐、前药或溶剂化合物来影响法尼基蛋白转移酶的抑制作用,其中:
A₁和A₂分别独立地为H、烷基、取代烷基、环烷基、取代环烷基、苯基或取代苯基;
G₁为S或O;
G₂为H、-C(O)OH、-C(O)NH₂、5-四唑基、-C(O)N(R₇)OH或-CH₂OH;
X为O或R₈N;
Y和Z分别独立为-CH₂-或-C(O)-;
R₁、R₂、R₃、R₄、R₅、R₆和R₇分别独立为H或烷基;
R₁也可以是烷酰基,
R₁和A₁一起可以是-(CH₂)m;
R₈为H、烷基、苯基、苯基烷基、取代苯基、(取代苯基)烷基或-C(O)R₉;
R₉为H、烷基、苯基、苯基烷基、取代苯基或(取代苯基)烷基;
m为3或4;
n为0、1或2;
p为0、1或2;和
q为0或1,但当p为0时,q也为0。